CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals

OXNARD, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has secured a new registration with the Drug Enforcement Administration (DEA) as a manufacturer authorized to handle Schedule 1 controlled substances. With this license, CURE will develop and manufacture cannabinoid-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif.

“This license enables CURE to translate the research findings from our collaboration with Technion – Israel Institute of Technology into potential treatments and expand our marketable product lines,” said

...read more at https://globenewswire.com/news-release/2018/11/26/1656495/0/en/CURE-Pharmaceutical-Secures-U-S-DEA-Approval-to-Manufacture-Cannabinoid-based-Pharmaceuticals.html

by

Leave a Reply